Epitope-based antibody claims have emerged to become one of the most important claim species in antibody patents. At the same time, they are heavily disputed. This article strives to give an overview about the as is situation both in Europe and the United States.
NevagiR.J.TothI. and SkwarczynskiM., Peptide-based vaccines, in: Peptide Applications in Biomedicine, Biotechnology and BioengineeringKoutsopoulosS., ed, Woodhead Publishing, 2017.
2.
DengX.StorzU. and DoranzB., Enhancing antibody patent protection using epitope mapping information, MAbs10(2) (2018 Feb-Mar), 204–209.
3.
GreslT.StorzU. and SandercockC., An update on obtaining and enforcing therapeutic antibody patent claims, Nature Biotechnology34(12) (2016), 1242–1244.
4.
Decision Ariad Pharmaceuticals et al. v. Eli Lilly and Company, 598 F.3d 1336 (Fed. Cir. 2010). 598 F.3d 1336(Fed. Cir. 2010).
Board of Appeal decision T512/94 or T735/00; https://www.epo.org/law-practice/case-law-appeals/advanced-search.html.
12.
StewartM.KentL.SmithA. and BassinderE., The special inventive step standard for antibodies. epi Information, February 2011.
13.
RigbyB., Is the European Patent Office’s approach to assessing obviousness of antibody inventions consistent? Expert Opin Ther Pat24(12) (2014 Dec), 283.
14.
Decision In re Deuel, 51 F.3d 1552, 1558, 34 USPQ2d 1210, 1215 (Fed. Cir. 1995).
15.
Market Research Report: Hyperlipidemia Drugs Market Analysis Report by Drug Class (Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Combination), and Segment Forecasts, 2016–2022. Grand View Research, 2016.
16.
PagliaruloN., Regeneron, Sanofi cuts PCSK9 list price, matching earlier move by rival Amgen, Biopharma Dive, Feb. 11, 2019.
17.
BGH Case 4c O 39/16.
18.
BPatG Case 3 Li 1/18.
19.
BGH Decision X ZB 2/19.
20.
Case 1:14-cv-01317, District Court of Delaware.
21.
ReinF.H.ZalcensteinA. and McGuinnessK., Amgen v. Sanofi: can an injunction contrary to the public health interest ever properly be granted? Journal of Generic Medicines2(14) (2018), 95–99.
22.
HerperM., Could Amgen’s Patent Victory Be Bad For Medicine? Forbes, Jan 6, 2017.
StorzU.CoxG. and DoranzB., Functional Antibody Patents Are Dead: Long Live Functional Antibody Patents, Panel at the BioConvention 2018 in Boston, Wednesday, June 6, 2018.
25.
AquinoJ.T., Antibody Claims Must Move Toward Structure, Panelists Say, Bloomberg BNA, Nov 20, 2017.
26.
Decision Amgen Inc., et al., Petitioners v. Sanofi, et al., Case No 18-127.
27.
NisenM., Esperion’s New Cholesterol Drug Needs More Than Good Results, Bloomberg Opinion, March 7, 2018.
Sanchez-TrincadoJ. et al., Fundamentals and Methods for T- and B-Cell Epitope Prediction, Journal of Immunology Research, Volume 2017, Article ID 2680160.
35.
http://www.cbs.dtu.dk/services/BepiPred/.
36.
Chapter 4 “Immunization with peptides”, in: BurdonR.H. and van KnippenbergP.H., eds, Synthetic Polypeptides as Antigens, 1988.
37.
SomaG. et al., Using epitope mapping to derive more value from mAbs, GenEngNews37(15) (September 1, 2017).
38.
WingroveP., SCOTUS antibody case refusal raises Section 112 uncertainty, PatentStrategy, 29 May 2019.
39.
WingroveP., SCOTUS antibody case refusal raises Section 112 uncertainty, PatentStrategy, 29 May 2019.
40.
Board of Appeal decision T018/09; https://www.epo.org/law-practice/case-law-appeals/advanced-search.html.
